Prof. Philippe Moreau
University Hospital of Nantes, Nantes, France
How do the latest data on novel therapies contribute to outcomes in RRMM?
The latest data on emerging therapeutic agents are discussed by the panel in the context of their potential application in clinical practice, to fulfil some of the key unmet needs in the management of RRMM.view bio and disclosures 3/4 Next Chapter
How can we move to a more personalized approach to RRMM treatment?
The panel discusses the need for a personalized approach to the management of patients with RRMM, the challenges posed by the complexity of the disease and how the latest advances will impact clinical practice.view bio and disclosures 4/4 Take CME Test
Overview & Learning Objectives
In this activity, a panel of experts in RRMM discusses the latest advances in the treatment of relapsed and/or refractory multiple myeloma and the potential for precision medicine.
This activity has been jointly provided by USF Health and touchIME.
This activity has been designed to meet the educational needs of oncology and haematology specialists who are involved in the management of patients with RRMM.
USF Health adheres to ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that faculty will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
Philippe Moreau discloses: Consultant/Advisory Board positions with AbbVie Inc., Amgen, Celgene/Bristol Myers Squibb, Janssen and Sanofi.
María-Victoria Mateos discloses: Consultant/Advisory Board positions with AbbVie, Adaptive, Amgen, Celgene, Genentech, GSK, Janssen, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi and Takeda. Speaker’s Bureau for Amgen, Celgene, GSK, Janssen and Takeda.
Pieter Sonneveld discloses: Consultant/Advisory Board positions with Amgen, Celgene, Janssen and Karyopharm. Grant/Research Support from Amgen, Celgene, Janssen and Karyopharm.
Subrena Powell, MSN, AGACNP-BC has no conflicts of interest to disclose.
Touch Medical Director
Sola Neunie has no financial interests/relationships or affiliations in relation to this activity.
USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
In order to receive credit for this activity participants must review and complete the post-test evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.
USF Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Advanced Practice Providers
Physician Assistants may claim a maximum of 0.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Date of original release: 8 December 2020. Date credits expire: 8 December 2021.
If you have any questions regarding credit please contact email@example.com
After watching this activity, participants should be better able to:
- Describe the current challenges in the treatment of multiple myeloma and considerations for overcoming poor prognosis
- Discuss the efficacy and safety data of novel agents being investigated in patients with RRMM
- Describe approaches to selecting treatment for patients with RRMM and the potential for precision medicine
Faculty & Disclosures
Prof. Philippe Moreau
University Hospital of Nantes, Nantes, France
Philippe Moreau, MD, serves as Professor of Clinical Hematology and head of the translational research program in hematology and oncology at the University Hospital of Nantes, France. Prof. Moreau’s clinical interests are focused on multiple myeloma and its treatment with high-dose therapy and novel agents. read more
Prof. Moreau is the chairman of the Intergroupe Francophone du Myélome (IFM). He has been vice-president of the International Myeloma Society (IMS) since 2019, and a member of the steering committee of the International Myeloma Working Group (IMWG) since 2013. He has served as the principal investigator (PI) or co-PI of many international randomized phase III clinical trials: Tourmaline (ixazomib for relapsed myeloma), Aspire (carfilzomib for relapsed myeloma), Endeavor (carfilzomib for relapsed myeloma), Stratus (pomalidomide for relapsed myeloma), Pollux (daratumumab for relapsed myeloma), Arrow (weekly versus biweekly carfilzomib for relapsed myeloma), Cassiopeia (daratumumab for frontline therapy in transplant eligible patients) and Ikema (isatuximab for relapsed myeloma). He was a member of the organizing committee for the 2011 International Myeloma Workshop in Paris.
Prof. Moreau’s research is widely published and he has authored or coauthored more than 300 peer-reviewed articles that have appeared in high-impact factor journals, including the New England Journal of Medicine, Journal of Clinical Oncology, Lancet, Lancet Oncology, and Blood. He is a member of the editorial boards of Blood and Blood Cancer Journal and is frequently invited to speak at international haematologic oncology meetings.
In 2018, Prof. Moreau received the Robert A. Kyle lifetime achievement award for his work in the field of multiple myeloma.
Philippe Moreau discloses:Consultant/Advisory Board positions with AbbVie Inc., Amgen, Celgene/Bristol Myers Squibb, Janssen and Sanofi.
Dr María-Victoria Mateos
University of Salamanca, Salamanca, Spain
María-Victoria Mateos, MD, PhD, is Consultant Physician in the Haematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. She is the director of the Myeloma Program and coordinates the Clinical Trials Unit in Salamanca’s University Hospital Haematology Department. read more
Dr Mateos’s areas of interest include multiple myeloma, the biology of plasma cells and new drug development. She serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials in elderly and smouldering multiple myeloma (MM) patients, which have profoundly influenced current options for treating these patient populations.
She is also a member of the International Myeloma Working Group (IMWG), the International Myeloma Society (IMS), the European Hematology Association (EHA) and the American Society of Hematology (ASH). She has published over 200 papers in peer-reviewed international journals, some of which have become key references in the MM field. She is Associate Editor for myeloma in Annals of Haematology (since 2011) and has acted as a reviewer for top journals such as the New England Journal of Medicine, Lancet and Lancet Oncology. Among her invited presentations, she has contributed to the educational sessions of EHA 2012, ASH 2013, ASCO 2015, EHA 2016, ASCO and ASH 2017. She served on the EHA’s Scientific Program Committee and Advisory Board from 2013 until 2017, and on the ASH Scientific Committee on plasma cell diseases from 2015 until 2017.
Dr Mateos was a Councillor on the EHA Board from 2015 for a 4-year mandate and is a member of the Steering Committee for the Society of Hematologic Oncology (SOHO), of the IMS board and of the European School of Haematology (ESH) Scientific Committee.
María-Victoria Mateos discloses:Consultant/Advisory Board positions with AbbVie, Adaptive, Amgen, Celgene, Genentech, GSK, Janssen, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi and Takeda. Speaker’s Bureau for Amgen, Celgene, GSK, Janssen and Takeda.
Prof. Pieter Sonneveld
Erasmus University, Rotterdam, The Netherlands
Pieter Sonneveld, MD, PhD was born in The Netherlands. He received his medical degree from Erasmus University in Rotterdam, The Netherlands in 1977. In 1980 he completed a PhD thesis on the pharmacology of adriamycin in acute leukemia at the University of Leiden. He received a Fogarty Fellowship and worked for several years at the National Cancer Institute, Bethesda, USA. read more
He is Professor of Hematology at the Erasmus MC and Erasmus University Rotterdam and has occupied the Chair of the Erasmus MC Cancer Institute in Rotterdam for 8 years. From 2011 to 2017 he was Head of the Department of Hematology. His research focus is on clinical and translational aspects of diagnostics and drug therapy in multiple myeloma. The myeloma research group in Erasmus MC has been very active in molecular diagnostics and prognostic systems. He has received numerous grants for his research.
Prof. Sonneveld is Chairman of the HOVON Myeloma Working Group and he coordinates HOVON and European Myeloma Network (EMN) clinical trials for multiple myeloma. He helped to found the EMN and has been its chairman since 2005. Within EMN, he coordinates a cooperative network for independent clinical trials in Europe and initiates efforts to create international standards for diagnostics and patient care.
He has been Board member (2011–present) and President (2017–19) of the European Hematology Association (EHA), and occupies the chair of its Scientific Working Group Committee. He has chaired the Scientific Program Committee of the 19th EHA congress in Milan 2014 and of the EMN Myeloma meetings in 2018 and 2020.
Prof. Sonneveld serves on the Scientific Advisory Boards of the International Myeloma Foundation (IMF) and the Multiple Myeloma Research Foundation (MMRF) and is a member of the International Myeloma Working Group. He has been a member of the Editorial Boards of Blood, Leukemia, European Journal of Cancer and Haematologica, and has authored more than 500 peer–reviewed scientific publications and several book chapters (H-factor 95).
In 2015 he was awarded the prestigious international Robert A. Kyle lifetime achievement award for his work in multiple myeloma. In 2019 he received the Hubertus Wald Award for Cancer Research from Germany.
Pieter Sonneveld discloses:Consultant/Advisory Board positions with Amgen, Celgene, Janssen and Karyopharm. Grant/Research Support from Amgen, Celgene, Janssen and Karyopharm.